Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Endpoints Capital was founded in 2023 to tackle the funding challenges faced by biotechnology companies in Australia. The firm focuses on providing tailored financing solutions for biotechs at all stages of development, particularly those engaged in preclinical and clinical trials. By offering non-dilutive funding against R&D tax incentives, Endpoints Capital enables biotechs to optimize their R&D spending and extend their runway without the burden of equity dilution.
Headquartered in Surry Hill, NSW, Endpoints Capital has quickly established itself in the biotech sector, funding over $70 million in R&D advances to 23 clients within its first 18 months. The firm operates with a team of experienced professionals, including individuals with extensive backgrounds in healthcare and finance. Their notable milestone includes the successful funding of Vaxxas Pty Ltd, which received AU$9.7 million to advance its vaccination technology.
Endpoints Capital specializes in financing biotechnology companies that qualify for R&D tax refunds. Their primary product, the Endpoints Accelerator Loan, allows biotechs to access their R&D tax incentives immediately. This approach optimizes R&D spending and delays the need for dilutive equity raising, which is particularly advantageous in the current equity climate.
The firm targets companies at various stages of development, including pre-seed, seed, and growth equity, with a strong emphasis on preclinical and clinical-stage biotechs. Ticket sizes for funding range from $150,000 to $11.2 million, providing flexibility for companies based on their specific needs. Endpoints Capital's investment strategy complements traditional venture capital funding, offering a vital alternative for biotechs seeking financial support.
Endpoints Capital has built a diverse portfolio of 23 biotechnology companies, focusing on those engaged in innovative research and development. A notable portfolio company is Vaxxas Pty Ltd, which received AU$9.7 million to advance its vaccination technology. This funding is part of Endpoints Capital's cumulative investment of over $70 million in R&D advances across its client base.
The firm’s portfolio reflects its commitment to supporting biotechs at various stages, particularly those eligible for R&D tax refunds. By providing immediate access to these funds, Endpoints Capital enables its clients to optimize their research spending and navigate the complexities of funding in the biotech sector.
Dr. Glenn Haifer - Chairman. Dr. Haifer has over 30 years of experience in the healthcare and life sciences industry, with a track record of successful exits to private equity and ASX-listed companies.
Doron Haifer - Head of Funding. Doron brings a strong background in strategy and finance, having previously worked with Boston Consulting Group (BCG).
Patrick Wales - Commercial Director. Patrick is a Chartered Accountant with expertise in finance operations, contributing to the firm's financial strategies.
Daniel Fihrer - Senior Credit Analyst. Daniel plays a key role in assessing funding opportunities and managing client relationships.
To pitch to Endpoints Capital, founders should use the application portal available on their website. It is important to include comprehensive details in the pitch deck, particularly regarding R&D activities and funding utilization. The firm prefers clear and concise presentations that highlight the potential impact of the proposed research.
Response times may vary, but founders can expect timely communication regarding their applications. Warm introductions are beneficial but not mandatory for the application process.
Endpoints Capital offers the Endpoints Accelerator Loan, which provides immediate access to R&D tax refunds for biotechnology companies. This program is designed to help biotechs optimize their research spending without the need for equity dilution.
Details regarding loan amounts, repayment terms, and application processes are available on their website, ensuring that interested companies can easily access the necessary information to apply.
Since its founding in 2023, Endpoints Capital has actively engaged with the biotech community, funding over $70 million in R&D advances to 23 biotech clients within its first 18 months. The firm is also associated with the upcoming Bioshares Biotech Summit scheduled for August 2025, indicating ongoing involvement in industry events.
Endpoints Capital continues to expand its presence in the biotech sector, providing essential non-dilutive funding solutions that enhance R&D capabilities for startups. Their commitment to supporting biotechs is evident through their significant funding activities and participation in industry discussions.
What are Endpoints Capital's investment criteria?
Endpoints Capital focuses on biotechnology companies in Australia that are eligible for R&D tax refunds. They provide financing solutions for companies at all stages of development, particularly those involved in preclinical and clinical trials.
How can I apply or pitch to Endpoints Capital?
Founders can apply for funding through the application portal on their website at Apply now. It is recommended to include detailed information about your R&D activities and how the funding will be utilized.
What makes Endpoints Capital different from traditional VCs?
Endpoints Capital offers non-dilutive financing solutions, allowing biotechs to access R&D tax incentives without giving up equity. This model is particularly beneficial in the current equity climate, providing a vital alternative for funding.
What is the typical check size for funding?
Endpoints Capital provides funding ranging from $150,000 to $11.2 million, depending on the specific needs of the biotech company.
What is the firm's geographic focus?
Endpoints Capital primarily focuses on biotechnology companies located in Australia, particularly those that are eligible for R&D tax refunds.
What kind of post-investment support does Endpoints Capital provide?
Endpoints Capital fosters long-term relationships with its portfolio companies, providing support throughout various stages of clinical trials and helping them navigate funding complexities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.